^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zalifrelimab (UGN-301)

    i
    Other names: UGN301, RebmAb 600, UGN 301, UGN-301, AGEN-1884, AGEN1884, RebmAb-600, AGEN 1884, RebmAb600
    Company:
    Agenus, Betta Pharma, Recepta
    Drug class:
    CTLA4 antagonist
    Related drugs:
    7ms
    Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas (clinicaltrials.gov)
    P2, N=65, Recruiting, University of Colorado, Denver | N=28 --> 65
    Enrollment change • Checkpoint inhibition
    |
    pegylated liposomal doxorubicin • balstilimab (AGEN2034) • botensilimab (AGEN1181) • zalifrelimab (UGN-301)
    10ms
    RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer (clinicaltrials.gov)
    P2, N=212, Active, not recruiting, Agenus Inc. | Trial primary completion date: Jan 2025 --> Aug 2025
    Trial primary completion date
    |
    balstilimab (AGEN2034) • zalifrelimab (UGN-301)
    10ms
    A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, UroGen Pharma Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • zalifrelimab (UGN-301) • Vesimune (imiquimod intravesical)
    11ms
    A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab (clinicaltrials.gov)
    P1/2, N=71, Recruiting, ImmunoGenesis
    New P1/2 trial
    |
    balstilimab (AGEN2034) • zalifrelimab (UGN-301) • evofosfamide (IMGS-101)
    11ms
    NUMANTIA: Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=28, Active, not recruiting, Nelum Corp | Trial completion date: Oct 2024 --> Apr 2025 | Trial primary completion date: Oct 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • zalifrelimab (UGN-301) • NLM-001
    11ms
    NUMANTIA: Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=28, Active, not recruiting, Nelum Corp | Trial completion date: Oct 2024 --> Apr 2025 | Trial primary completion date: Oct 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • zalifrelimab (UGN-301) • NLM-001
    12ms
    RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer (clinicaltrials.gov)
    P2, N=212, Active, not recruiting, Agenus Inc. | Trial primary completion date: Aug 2024 --> Jan 2025
    Trial primary completion date • Combination therapy
    |
    balstilimab (AGEN2034) • zalifrelimab (UGN-301)
    1year
    Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas (clinicaltrials.gov)
    P2, N=28, Recruiting, University of Colorado, Denver | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Checkpoint block • Metastases
    |
    pegylated liposomal doxorubicin • balstilimab (AGEN2034) • botensilimab (AGEN1181) • zalifrelimab (UGN-301)
    over1year
    rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG (clinicaltrials.gov)
    P1, N=36, Recruiting, Ann & Robert H Lurie Children's Hospital of Chicago | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Checkpoint block
    |
    balstilimab (AGEN2034) • zalifrelimab (UGN-301)
    over1year
    A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov)
    P1, N=60, Recruiting, UroGen Pharma Ltd. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    gemcitabine • zalifrelimab (UGN-301) • Vesimune (imiquimod intravesical)
    over1year
    AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer (clinicaltrials.gov)
    P2, N=4, Terminated, The University of Texas Health Science Center at San Antonio | Active, not recruiting --> Terminated; PI left the institution
    Trial termination • Combination therapy
    |
    cisplatin • gemcitabine • balstilimab (AGEN2034) • zalifrelimab (UGN-301)
    over1year
    A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Agenus Inc. | N=177 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Combination therapy • Metastases
    |
    balstilimab (AGEN2034) • zalifrelimab (UGN-301)